Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of zanubrutinib combined with g-CVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisone) for first-line treatment of follicular lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JXJieyu XuHYHaiyan Yang

Discussion

Loading...

Member takes

Overview

Retrospective analysis demonstrates improved complete response rates in follicular lymphoma using zanubrutinib and G-CVP, indicating effective first-line treatment.

Key Points

  • This study aims to evaluate the efficacy and safety of zanubrutinib combined with G-CVP as first-line therapy for follicular lymphoma.
  • Retrospective analysis of untreated follicular lymphoma patients receiving ZG-CVP regimen from July 2024 to June 2025.
  • Patients were assessed for response rates and adverse events according to CTCAE criteria.
  • Treatment involved zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, and prednisone over six cycles.
  • 23 patients analyzed, with 100% achieving complete response after 6 cycles.
  • High response rates: 95.2% complete response rate and 100% overall response rate after 4 cycles.
  • Most common adverse events were anemia (56.5%), neutropenia (47.8%), and thrombocytopenia (47.8%).

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1f2https://doi.org/10.1182/blood-2025-7103
View Full Paper
Ask AI
Bookmark
Share